FDA Covid-19 Response
FDA is working with U.S. Government partners, including CDC, and international partners to address the pandemic.
Featured Topics

New Era of Smarter Food Safety
A new approach to food safety that recognizes and builds on the progress made in the past but looks towards what processes and tools will be needed for the future.

Fostering Drug Competition
Increasing the availability of generic drugs helps to create competition in the marketplace, helping make treatment more affordable and increasing access to healthcare for more patients.

Combating the Opioid Crisis
FDA takes actions to combat prescription opioid abuse.
Recent Press Announcements
Recalls, Market Withdrawals, & Safety Alerts
The FDA provides information gathered from press releases and other public notices about certain recalls of FDA-regulated products. Not all recalls have press releases or are posted on this website
Feb 26
J&J Distributing Recalls Multiple Products Because of Possible Health Risk
Food & Beverages
Feb 23
Medtronic Announces Voluntary Recall of Unused Valiant Navion™ Thoracic Stent Graft System
Medical Devices
Feb 22
Urban Remedy Voluntarily Recalls Beverages with Undeclared Almond & Cashew Allergens
Food & Beverages
FDA VOICES: PERSPECTIVES FROM FDA EXPERTS

Reflections on a Record Year for Novel Device Innovation Despite COVID-19 Challenges
FDA achieved a record number of novel medical device authorizations in 2020.

FDA’s Generic Drug Program in 2020 Helped Ensure Availability of High-Quality, Affordable Drugs Amid COVID-19
In 2020, the FDA’s generic drug program moved steadily forward even as the COVID-19 pandemic presented additional complexities.

FDA Steps Up Efforts to Protect Consumers from Food Allergens
FDA uses its authorities to help protect those with food allergies.
Recently Published Guidances
Feb 22
Development of Monoclonal Antibody Products Targeting SARS-CoV-2, Including Addressing the Impact of Emerging Variants, During the COVID 19 Public Health Emergency
Drugs
Feb 22
Emergency Use Authorization for Vaccines to Prevent COVID-19
Biologics
Feb 22
Policy for Evaluating Impact of Viral Mutations on COVID-19 Tests
Medical Devices